UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clonal relationship in multisited mucosa‐associated lymphoid tissue lymphomas: a single‐centre experience

British journal of haematology, 2021-03, Vol.192 (6), p.1020-1025

2021

Volltextzugriff (PDF)

Are Biosimilars the Future of Oncology and Haematology?

Drugs (New York, N.Y.), 2019-10, Vol.79 (15), p.1609-1624

2019

Volltextzugriff (PDF)

Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study

Haematologica (Roma), 2022-07, Vol.107 (7), p.1633-1642

2022

Volltextzugriff (PDF)

Efficacy and safety of offline extracorporeal photopheresis in cutaneous T-cell lymphomas: A retrospective study

Photodermatology, photoimmunology & photomedicine, 2023-11, Vol.39 (6), p.667-669

2023

Volltextzugriff (PDF)

Fludarabine, Cyclophosphamide, and Mitoxantrone as Initial Therapy of Chronic Lymphocytic Leukemia: High Response Rate and Disease Eradication

Clinical cancer research, 2008-01, Vol.14 (1), p.155-161

2008

Volltextzugriff (PDF)

Long‐term outcome comparing histological grades of follicular lymphoma patients treated with immunochemotherapy as first‐line therapy: A retrospective analysis from two institutions

European journal of haematology, 2020-03, Vol.104 (3), p.198-206

2020

Volltextzugriff (PDF)

Clinicopathologic features and prognostic significance of CD30 expression in de novo diffuse large B-cell lymphoma (DLBCL): results in a homogeneous series from a single institution

Biomarkers, 2020-01, Vol.25 (1), p.69-75

2020

Volltextzugriff (PDF)

Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study

The lancet oncology, 2020-07, Vol.21 (7), p.978-988

2020

Volltextzugriff (PDF)

Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era

Frontiers in immunology, 2022-07, Vol.13, p.909008-909008

González Barca, Eva

2022

Volltextzugriff (PDF)

Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era

European journal of haematology, 2010-10, Vol.85 (4), p.321-328

2010

Volltextzugriff (PDF)

Long-term follow-up of patients with HIV-related diffuse large B-cell lymphomas treated in a phase II study with rituximab and CHOP

British journal of haematology, 2012-06, Vol.157 (5), p.637-639

2012

Volltextzugriff (PDF)

Multiplex ligation‐dependent probe amplification for detection of genomic alterations in chronic lymphocytic leukaemia

British journal of haematology, 2008-09, Vol.142 (5), p.793-801

2008

Volltextzugriff (PDF)

Expert Consensus on the Characteristics of Patients with Epstein–Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) for Whom Standard-Dose Chemotherapy May be Inappropriate: A Modified Delphi Study

Advances in therapy, 2023-03, Vol.40 (3), p.1267-1281

2023

Volltextzugriff (PDF)

Developing New Strategies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Journal of clinical medicine, 2023-11, Vol.12 (23), p.7376

Gonzalez Barca, Eva

2023

Volltextzugriff (PDF)

Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL

Leukemia & lymphoma, 2022-07, Vol.63 (9), p.2063-2073

2022

Volltextzugriff (PDF)

Incidence and management of patients with methotrexate delayed elimination in the clinical practice: A Delphi study

Journal of oncology pharmacy practice, 2023-06, Vol.29 (4), p.794-801

2023

Volltextzugriff (PDF)

Validation of the NCCN-IPI and the GELTAMO-IPI for diffuse large B-Cell lymphoma treated with R-CHOP in a large cohort of patients from a single institution

Leukemia & lymphoma, 2020-02, Vol.61 (3), p.575-581

2020

Volltextzugriff (PDF)

Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

Haematologica (Roma), 2021-09, Vol.106 (9), p.2417-2426

2021

Volltextzugriff (PDF)

Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma

Blood advances, 2021-11, Vol.5 (22), p.4762-4770

2021

Volltextzugriff (PDF)

The prohibitin-binding compound fluorizoline induces apoptosis in chronic lymphocytic leukemia cells through the upregulation of NOXA and synergizes with ibrutinib, 5-aminoimidazole-4-carboxamide riboside or venetoclax

Haematologica (Roma), 2017-09, Vol.102 (9), p.1587-1593

2017

Volltextzugriff (PDF)

P1138: FIVE‐YEAR EFFICACY AND SAFETY OF TAFASITAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY DLBCL: FINAL RESULTS FROM THE PHASE II L‐MIND STUDY

HemaSphere, 2023-08, Vol.7 (S3), p.e4580941-n/a

2023

Volltextzugriff (PDF)

1 – 25 von 200

Suche als RSS-Feed

Aktive Filter

ThemaAged

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(190)
Mit Volltextzugriff
(176)

Publikationsform

Artikel
(199)
Berichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(57)
Life Sciences & Biomedicine
(56)
Hematology
(36)
Humans
(31)
Oncology
(22)
Lymphoma
(20)
Chronic Lymphocytic Leukemia
(15)
Cancer
(11)
Male
(11)
Prognosis
(11)
Chemotherapy
(10)
Leukemia
(10)
Biological And Medical Sciences
(9)
Diffuse Large B-Cell Lymphoma
(9)
Female
(9)
Medical Sciences
(9)
Patients
(9)
Hematologic And Hematopoietic Diseases
(7)
Immunotherapy
(7)
Limfomes
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(91)
Haematologica
(16)
Clinical Lymphoma, Myeloma And Leukemia
(10)
Journal Of Clinical Oncology
(9)
British Journal Of Haematology
(4)
Cancer Research
(4)
Medicina Clínica
(4)
Infectious Agents And Cancer
(3)
Leukemia & Lymphoma
(3)
Oncotarget
(3)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Clonal relationship in multisited mucosa‐associated lymphoid tissue lymphomas: a single‐centre experience

Are Biosimilars the Future of Oncology and Haematology?

Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study

Efficacy and safety of offline extracorporeal photopheresis in cutaneous T-cell lymphomas: A retrospective study

Fludarabine, Cyclophosphamide, and Mitoxantrone as Initial Therapy of Chronic Lymphocytic Leukemia: High Response Rate and Disease Eradication

Long‐term outcome comparing histological grades of follicular lymphoma patients treated with immunochemotherapy as first‐line therapy: A retrospective analysis from two institutions

Clinicopathologic features and prognostic significance of CD30 expression in de novo diffuse large B-cell lymphoma (DLBCL): results in a homogeneous series from a single institution

Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study

Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era

Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era

Long-term follow-up of patients with HIV-related diffuse large B-cell lymphomas treated in a phase II study with rituximab and CHOP

Multiplex ligation‐dependent probe amplification for detection of genomic alterations in chronic lymphocytic leukaemia

Rituximab maintenance after bendamustine-based treatment for follicular lymphoma and mantle cell lymphoma may exert a negative influence on SARS-CoV-2 infection outcomes

Expert Consensus on the Characteristics of Patients with Epstein–Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) for Whom Standard-Dose Chemotherapy May be Inappropriate: A Modified Delphi Study

Developing New Strategies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL

Incidence and management of patients with methotrexate delayed elimination in the clinical practice: A Delphi study

Validation of the NCCN-IPI and the GELTAMO-IPI for diffuse large B-Cell lymphoma treated with R-CHOP in a large cohort of patients from a single institution

Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma

Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

The prohibitin-binding compound fluorizoline induces apoptosis in chronic lymphocytic leukemia cells through the upregulation of NOXA and synergizes with ibrutinib, 5-aminoimidazole-4-carboxamide riboside or venetoclax

Using the Lymph2Cx assay for assessing cell-of-origin subtypes of HIV-related diffuse large B-cell lymphoma

Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC)

P1138: FIVE‐YEAR EFFICACY AND SAFETY OF TAFASITAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY DLBCL: FINAL RESULTS FROM THE PHASE II L‐MIND STUDY

Aktive Filter

Suchergebnisse filtern